NFKB1 and Cholestatic liver disease: We focused on the effects of AMPK-mediated signaling and the NF-κB pathway as well as the MAPK-related signaling in cholestatic liver diseases and evaluated the protective role of AICAR against hepatic injury and fibrosis triggered by cholestasis-related inflammation.